PubRank

I M Robbins

Author PubWeight™ 23.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001 6.88
2 Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000 4.07
3 Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000 1.80
4 Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003 1.76
5 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004 1.73
6 Fatal Scopulariopsis infection in a lung transplant recipient: lessons of organ procurement. Am J Transplant 2014 1.48
7 The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 2005 1.09
8 Percutaneous pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis. Am J Respir Crit Care Med 2001 1.03
9 T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir Med 2009 0.98
10 Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004 0.89
11 Iatrogenic paradoxical air embolism in pulmonary hypertension. Chest 2001 0.84
12 Pulmonary artery stenosis and fibrous mediastinitis. Chest 2001 0.83
13 Pulmonary vasoreactivity in PPH. J Am Coll Cardiol 2001 0.81
14 An interesting electrolyte problem. Postgrad Med J 2000 0.75